ArticleFrontiers in pharmacology2022
Astragaloside IV Relieves Atherosclerosis and Hepatic Steatosis
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 24 citations in OpenAlex.
- Protective effects of Astragaloside IV on various liver diseases: From chemistry to herbal medicines (Review).International journal of molecular medicine · 2026Review
- Pathological mechanisms of inflammatory responses in atherosclerosis and the multi-target regulatory effects of traditional Chinese medicine.Frontiers in cardiovascular medicine · 2026Review
- Research Progress on Chemical Components ofMolecules (Basel, Switzerland) · 2025Review
- Targeting Telomere Shortening in Vascular Aging and Atherosclerosis: Therapeutic Promise ofJournal of cardiovascular development and disease · 2025Review
- Uncovering the molecular mechanisms of tonifying kidney and activating blood Decoction against myocardial fibrosis using network Pharmacology and experimental validation.Scientific reports · 2025Article
- Uncovering the Role of Anmeidan against Atherosclerosis from Integrated Network Pharmacology and Pharmacological Experiments.Combinatorial chemistry & high throughput screening · 2025Article
- Recent advances in the interaction of ferroptosis and immune-mediated inflammation in cardiovascular disease: mechanisms and therapeutic potential.Frontiers in immunology · 2025Review
- Potential of herbal formulas and bioactive metabolites in treating atherosclerosis: targeted modulation of macrophage polarization.Frontiers in pharmacology · 2025Review
- A Review of the Mechanisms of Astragaloside IV and Berberine in Vascular Dysfunction Associated with Obesity and Diabetes.Drug design, development and therapy · 2025Review
- Oleanolic Acid@SPIONs Alleviates Lipid-Oxidative Stress Injury of Zebrafish Blood Vessels via Regulating the Expression of JNK and MAPK Signaling Pathways in Vascular Endothelial Cells.Drug design, development and therapy · 2025Article
- Effectiveness and Safety of Qishen Yiqi Dripping Pill in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: 3-Year Results from a Multicentre Cohort Study.Chinese journal of integrative medicine · 2024Article
- Effect of High Magnesium and Astragaloside IV on Vascular Endothelial Cells.Cell biochemistry and biophysics · 2024Article
- Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.Heliyon · 2024Article
- Recent advances of traditional Chinese medicine against cardiovascular disease: overview and potential mechanisms.Frontiers in endocrinology · 2024Review
- Could Cyclosiversioside F Serve as a Dietary Supplement to Prevent Obesity and Relevant Disorders?International journal of molecular sciences · 2023Review
- Review on the protective mechanism of astragaloside IV against cardiovascular diseases.Frontiers in pharmacology · 2023Review
- Effects and Potential Mechanism of Zhuyu Pill Against Atherosclerosis: Network Pharmacology and Experimental Validation.Drug design, development and therapy · 2023Article
- Mechanism of Tao Hong Decoction in the treatment of atherosclerosis based on network pharmacology and experimental validation.Frontiers in cardiovascular medicine · 2023Article
- Astragaloside IV improves renal function and alleviates renal damage and inflammation in rats with chronic glomerulonephritis.Turkish journal of biology = Turk biyoloji dergisi · 2023Article
- Untapping the Potential of Astragaloside IV in the Battle Against Respiratory Diseases.Drug design, development and therapy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Astragaloside IV (AS-IV) is the main active compound of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.